Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes

Haematologica

Volumn 102, Issue 2, 2017, Pages 320-326

  Cremers, Eline M P ^a   Westers, Theresia M ^a   Alhan, Canan ^a   Cali, Claudia ^a   Visser Wisselaar, Heleen A ^b   Chitu, Dana A ^b   van der Velden, Vincent H J ^c   te Marvelde, Jeroen G ^c   Klein, Saskia K ^d   Muus, Petra ^e   Vellenga, Edo ^f   de Greef, Georgina E ^b   Legdeur, Marie Cecile C J C ^g   Wijermans, Pierre W ^h   Stevens Kroef, Marian J P L ^e   da Silva Coelho, Pedro ^e   Jansen, Joop H ^e   Ossenkoppele, Gert J ^a   van de Loosdrecht, Arjan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g MEDISCH SPECTRUM TWENTE   (Netherlands)

^h HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD36 ANTIGEN; CD45 ANTIGEN; CD71 ANTIGEN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BONE MARROW; CELL STRUCTURE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DYSERYTHROPOIESIS; ERYTHROCYTE; ERYTHROID CELL; FLOW CYTOMETRY; GENE EXPRESSION; GRANULOCYTE; HUMAN; MAJOR CLINICAL STUDY; MEGAKARYOPOIESIS; MONOCYTE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL LINE; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; CELL LINEAGE; FEMALE; IMMUNOPHENOTYPING; MALE; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; CELL LINEAGE; ERYTHROID CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 85011627904     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.147843     Document Type: Article

References (31)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114 (5): 937–951.
2. Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122 (17): 2943–2964.
3. van de Loosdrecht AA, Alhan C, Béné MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009; 94 (8): 1124–1134.
4. Porwit A, van de Loosdrecht AA, Bettelheim P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014; 28 (9): 1793–1798.
5. Chopra A, Pati H, Mahapatra M, et al. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches. Ann Hematol. 2012; 91 (9): 1351–1362.
6. Matarraz S, López A, Barrena S, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom. 2010; 78 (3): 154–168.
7. Wells D, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003; 102 (1): 394–403.
8. van de Loosdrecht AA, Ireland R, Kern W, et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma. 2013; 54 (3): 472–475.
9. Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer. 2010; 116 (19): 4549–4563.
10. Lorand-Metze I, Ribeiro E, Lima CSP, et al. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with nonclonal disorders. Leuk Res. 2007; 31 (2): 147–155.
11. Malcovati L, Della Porta MG, Lunghi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2005; 19 (5): 776–783.
12. Xu F, Li X, Chang C-K, et al. Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes. PLoS One. 2014; 9 (2): e88706.
13. Della Porta MG, Picone C, Pascutto C, et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica. 2012; 97 (8): 1209–1217.
14. Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009; 94 (8): 1066–1074.
15. Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012; 26 (7): 1730–1741.
16. Van de Loosdrecht A, Westers T. Cutting edge: flow cytometry in myelodysplastic syndromes. J Natl Compr Canc Netw. 2013; 11 (7): 892–902.
17. Cremers EMP, Westers TM, Alhan C, et al. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. Eur J Cancer. 2016; 54: 49–56.
18. Germing U, Strupp C, Giagounidis A, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res. 2012; 36 (6): 727–734.
19. Xu F, Wu L, He Q, et al.Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes. Intern Med J. 2012; 42 (4): 401–411.
20. Fajtova M, Kovarikova A, Svec P, et al. Immunophenotypic profile of nucleated erythroid progenitors during maturation in regenerating bone marrow. Leuk Lymphoma. 2013; 54 (11): 2523–2530.
21. Eidenschink Brodersen L, Menssen AJ, Wangen JR, et al. Assessment of erythroid dysplasia by “Difference from normal” in routine clinical flow cytometry workup. Cytometry B Clin Cytom. 2015; 88 (2): 125-135.
22. Mathis S, Chapuis N, Debord C, et al. Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia. 2013; 27 (10): 1981–1987.
23. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100 (7): 2292–2302.
24. Westers TM, van der Velden VHJ, Alhan C, et al. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS. Leuk Res. 2012; 36 (4): 422–430.
25. Cutler J, Wells D, van de Loosdrecht AA, et al. Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias. Cytometry B Clin Cytom. 2011; 80 (3): 150–157.
26. Maassen A, Strupp C, Giagounidis A, et al. Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk Res. 2013; 37 (1): 64–70.
27. Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia. 2015; 29 (1): 66–75.
28. Bardet V, Wagner-Ballon O, Guy J, et al. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015; 100 (4): 472–478.
29. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28 (2): 241-247.
30. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122 (22): 3616-3627.
31. Genovese G, Kähler AK, Handsaker RE, et al. Clonal Hematopoiesis and Blood- Cancer Risk Inferred from Blood DNA Sequence. N Engl J Med. 2014 Dec 25; 371 (26): 2477-2487.